Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 138

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 138
---
 from the manufacture of Consumer Healthcare products on behalf of legal entities within Opella; those revenues are presented within Other Revenues in the income statement. The Biopharma operating segment also includes the the purchase price of Biopharma products manufactured by legal entities within the Opella scope. The “Other” category comprises primarily, but not exclusively, Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights). Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2/ Business operating income (non-IFRS financial measure) We report segment results on the basis of “Business operating income.” This non-IFRS indicator is used internally by Sanofi’s chief operating decision maker to measure the performance of our operating segmen t and to allocate resources. For a definition of “Business operating income,” and a reconciliation between that indicator and IFRS Income before tax and investments accounted for using the equity method , refer to Note D.35. to our consolidated financial statements included at Item 18. of this annual report. “Business operating income” is a non-IFRS financial measure and is reconciled with IFRS Operating income . IFRS Operating income for 2024 amounted to €7,252 million, versus €6,960 million for 2023 and € 10,162 million for 2022; refer to Note D.35. to our consolidated financial statements included at Item 18. of this annual report . Our “Business operating income” for 2024 amounted to € 11,343 million, versus € 11,178 million in 2023 and € 12,793 million